SENATE BILL 557

J1

9lr2747 CF HB 660

By: **Senator Eckardt** Introduced and read first time: February 4, 2019 Assigned to: Education, Health, and Environmental Affairs

A BILL ENTITLED

1 AN ACT concerning

2 Public Health – Tick–Borne Disease Interagency Workgroup

3 FOR the purpose of establishing the Tick–Borne Disease Interagency Workgroup; 4 providing for the composition, chair, and staffing of the Workgroup; requiring the $\mathbf{5}$ Workgroup to hold certain meetings; prohibiting a member of the Workgroup from 6 receiving certain compensation, but authorizing the reimbursement of certain 7 expenses; requiring the Workgroup to solicit input from certain stakeholders and 8 study and make recommendations regarding certain matters; requiring the 9 Workgroup to submit an interim and a final report to certain committees of the General Assembly on or before certain dates; providing for the termination of this 1011 Act; and generally relating to the Tick–Borne Disease Interagency Workgroup.

12 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,13 That:

- 14 (a) There is a Tick–Borne Disease Interagency Workgroup.
- 15 (b) The Workgroup consists of the following members:
- 16 (1) one member of the Senate of Maryland, appointed by the President of17 the Senate;
- 18 (2) one member of the House of Delegates, appointed by the Speaker of the
- 19 House;
- 20 (3) the Secretary of Health, or the Secretary's designee;
- 21 (4) the Secretary of Agriculture, or the Secretary's designee;
- 22 (5) the Secretary of the Environment, or the Secretary's designee;

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.



	2		SENATE BILL 557	
1		(6)	the Secretary of Natural Resources, or the Secretary's designee;	
$\frac{2}{3}$	Center;	(7)	one representative of the University of Maryland Agricultural Research	
4 5	Council;	(8)	one representative of the University of Maryland Global Leadership	
6		(9)	seven members, appointed by the Secretary of Health, representing:	
7 8	tick–borne	disease	(i) health care providers with experience diagnosing and treating s;	
9			(ii) scientists or researchers with expertise in tick–borne diseases;	
10			(iii) patients with tick-borne diseases and their family members; and	
11 12	tick–borne	disease	(iv) nonprofit organizations that advocate for patients with s; and	
$\begin{array}{c} 13\\14\\15\end{array}$	(10) representatives of other State agencies, the Johns Hopkins School of Public Health, the University of Maryland Medical System, and the Maryland Hospital Association, as determined by the Secretary of Health.			
$\begin{array}{c} 16 \\ 17 \end{array}$	(c) The members of the Workgroup described in subsection (b)(9) and (10) of this section shall represent a diversity of scientific disciplines and views.			
18	(d)	The S	ecretary of Health shall designate the chair of the Workgroup.	
19	(e)	The I	laryland Department of Health shall provide staff for the Workgroup.	
20	(f)	The V	Vorkgroup shall meet at least twice annually.	
21	(g)	(g) A member of the Workgroup:		
22		(1)	may not receive compensation as a member of the Workgroup; but	
$\frac{23}{24}$	Travel Reg	(2) ulation	is entitled to reimbursement for expenses under the Standard State , as provided in the State budget.	
$25 \\ 26 \\ 27$	(h) The purpose of the Workgroup is to provide subject matter expertise and to review activities of federal and State agencies related to tick-borne diseases to ensure interagency coordination, minimize overlap, and examine research priorities.			
28	(i)	The V	Vorkgroup shall:	
29		(1)	review:	

SENATE BILL 557

1 (i) ongoing tick-borne disease research, including research related $\mathbf{2}$ to causes, prevention, treatment, surveillance, diagnosis, duration of illness, and 3 intervention for individuals with tick-borne diseases; and 4 (ii) federal and State activities related to tick-borne diseases, $\mathbf{5}$ including: 6 1. epidemiological activities; 7 2.basic, clinical, and translational tick-borne disease 8 research related to the pathogenesis, prevention, diagnosis, and treatment of tick-borne 9 diseases; and 10 3. actions undertaken by federal agencies and researchers, 11 including the federal Department of Health and Human Services and the National 12Institutes of Health; 13(2)solicit input from stakeholders, including organizations representing 14patients, health care providers, researchers, and industry, regarding scientific advances, 15research questions, surveillance activities, and emerging strains in species of pathogenic 16organisms; 17(3)develop a summary of: 18 the research, activities, and actions reviewed under item (1) of (i) 19 this subsection, including advances made as a result of the research, and gaps in the 20research: 21(ii) the Workgroup's meetings; and 22public comments received by the Workgroup; and (iii) make recommendations regarding any appropriate changes, including 23(4)24improvements, that should be made regarding research and activities regarding tick-borne 25diseases. 26On or before December 1, 2019, the Workgroup shall submit an interim (j) (1)27report of its findings and recommendations to the Senate Education, Health, and 28Environmental Affairs Committee and the House Health and Government Operations 29Committee in accordance with § 2–1246 of the State Government Article. 30 (2)On or before December 1, 2020, the Workgroup shall submit a final 31report of its findings and recommendations to the Senate Education, Health, and 32Environmental Affairs Committee and the House Health and Government Operations

33 Committee in accordance with § 2–1246 of the State Government Article.

SENATE BILL 557

1 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect July 2 1, 2019. It shall remain effective for a period of 2 years and, at the end of June 30, 2021, 3 this Act, with no further action required by the General Assembly, shall be abrogated and 4 of no further force and effect.